Consensus recommendations |
Grade |
All individuals with chronic HCV infection should be considered for antiviral therapy. |
A1 |
Choice of treatment regimen should be based on:
Women of childbearing potential should be cautioned to avoid pregnancy while receiving DAA treatment. |
B1 A1 B1 |
People who are treatment-naive (see Table 2) |
|
First-line treatment regimens that are pan-genotypic include:
|
A1 |
Recommended treatment regimens for chronic Gt 1 HCV infection and compensated liver disease include:
|
A1 |
Recommended treatment regimens for chronic Gt 2 HCV infection and compensated liver disease are:
|
A1 |
Recommended treatment regimens for chronic Gt 3 HCV infection and compensated liver disease include:
|
A1 |
Recommended treatment regimens for chronic Gt 4 HCV infection and compensated liver disease include:
|
A1 |
Recommended treatment regimens for chronic Gt 5/6 HCV infection and compensated liver disease include:
|
A1 |
People in whom DAA therapy has failed (see Table 3) |
|
People in whom first-line DAA therapy fails should be referred to a specialist centre for consideration of salvage therapy. |
B1 |
The recommended treatment regimen for people with compensated liver disease in whom first-line DAA therapy has failed is:
|
A1 |
Dose reduction or dose interruption of DAA therapies is not recommended. |
A1 |
Dose reduction of ribavirin for the management of symptomatic anaemia according to the product information is appropriate and will not reduce the likelihood of SVR. |
A1 |
DAA therapies for HCV should not be used in combinations other than those that have demonstrated efficacy in prospective clinical trials. |
B1 |